The Japanese pharmaceutical industry: Its evolution and current challenges

The Japanese Pharmaceutical Industry: Its Evolution and Current Challenges

Volumn , Issue , 2011, Pages 1-186

  Umemura, Maki ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84909598964     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4324/9780203831281     Document Type: Book

References (448)

1. Aizawa, Minoru., and United Nations Industrial Development Organization. Review of the Development of Antibiotic Industry in Selected Countries: Technical Report: Antibiotic Industry in Japan, History and Development, 74-77. Vienna: United Nations Industrial Development Organization, 1985.
2. Aflac Japan., Gan no Chiryo ni Kakawaru Keizaiteki Anketo [Questionnaire on Economic Costs of Cancer Treatment]. Tokyo: Aflac Japan, 2003.
3. American Board of Medical Specialties., '2008 ABMS Certificate Statistics'. http://www. abms.org/ (accessed 9 April 2010).
4. American Chamber of Commerce in Japan FDI Task Force., 'Pharmaceuticals.' Specific Policy Recommendation 3, February 2004, 3.
5. Amsden, Alice H., The Rise of 'The Rest': Challenges to the West from Late-industrializa- tion Economies. Oxford: Oxford University Press, 2001.
6. Amsden, Alice H., and Takashi Hikino. 'Staying Behind, Stumbling Back, Sneaking Up, Soaring Ahead: Late Industrialization in Historical Perspective'. In Convergence of Productivity: Cross-national Studies and Historical Evidence, edited by William J. Baumol, Richard R. Nelson, and Edward N. Wolff, 285-315. Oxford: Oxford University Press, 1994.
7. Anchordoguy, Marie., Reprogramming Japan: The High Tech Crisis under Communitarian Capitalism. Ithaca, NY: Cornell University Press, 2005.
8. Anegawa, Tomofumi., 'Nihon no Iyakuhin Sangyo: Sono Seiko to Shippai [The Japanese Pharmaceutical Industry: Its Success and Failure]'. Iryo to Shakai 12, no. 2 (2002): 49-78.
9. Aoyagi, Junichi., Inochi o Kangaete 85-nen: Banyu Seiyaku no Ayumi [85 Years for Life: The History of Banyu]. Tokyo: Banyu Pharmaceutical, Co. 2000.
10. Astellas Pharma., Inc. Annual Report 2009. Tokyo: Astellas Pharma, Inc., 2009.
11. Astellas Pharma., Yuka Shoken Hokokusho. Tokyo: Okurasho Insatsukyoku, 2006.
12. Ball, Peter., 'The Quinolones: History and Overview'. In The Quinolones, edited by Vincent T. Andriole, 1-33. San Diego: Academic Press, Inc., 1988.
13. Bank of Tokyo-Mitsubishi, Ltd., 'Honkakuteki na Kyoso Jidai o Mukaeru Iyakuhin Gyokai [The Pharmaceutical Industry to Face an Era of Serious Competition]'. Chosa Geppo [Monthly Research Report] 107 (February 2005): 1-9.
14. Barral, PE., 20 Years of Pharmaceutical Research Results Throughout the World. Antony: Rohne-Poulenc Rorer Foundation, 1996.
15. Bartholomew, James R., The Formation of Science in Japan. New Haven: Yale University Press, 1989.
16. Berndt, Ernst., 'Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price'. The Journal of Economic Perspectives 16, no. 4 (2002): 45-66.
17. Bonney, Rosemary C., SCRIP's Guide to Cancer Therapies: A Biotech Revolution? Richmond: Scrip Reports, 2001.
18. Broach, James R, and Jeremy Thorner., 'High-throughput Screening for Drug Discovery'. Nature 384 (November 1996): 14-16.
19. Brody, Jane E., 'Japanese Study Use of Toxins in Cancer Treatment'. The New York Times, 24 January 1968.
20. Brown, Jeffrey S., Brigitta Bienz-Tadmor and Louis Lasagna. 'Availability of Anticancer Drugs in the United States, Europe, and Japan from 1960 through 1991'. Clinical Pharmacology and Therapeutics 58 (September 1995): 243-256.
21. Bud, Robert F., 'Strategy in American Cancer Research after World War II: A Case Study'. Social Studies of Science 8 (November 1978): 425-459.
22. Cancer Research UK., 'Our History'. http://info.cancerresearchuk.org/cancerandresearch/ historyandachievements/ourhistory/ (accessed 1 December 2007).
23. Carter, Susan B., Scott Sigmund Gartner, Michael R. Haines, Alan L. Olmstead, Richard Sutch and Gavin Wright, eds., 'Death Rate, by Cause: 1900-1998.' Table Ab929-951. In Historical Statistics of the United States, Earliest Times to the Present: Millennial Edition. New York: Cambridge University Press, 2006.
24. Centre for Medicines Research International., 'Japan in Focus: Strategies for Innovation and Global Drug Development. What Differentiates Japanese Pharma Companies from their Western Counterparts'. R&D Briefing 28 (1999): 1-8.
25. Chandler, Alfred D., Shaping the Industrial Century: The Remarkable Story of the Modern Chemical and Pharmaceutical Industries. Cambridge, MA: Harvard University Press, 2005.
26. Charlton, John, and Mike Murphy, eds., 'Trends in Causes of Mortality: 1841-1994-An Overview'. In The Health of Adult Britain, 30-57. London: Stationery Office, 1997.
27. Chugai Pharmaceutical Co., Yiika Shoken Hokokusho [Annual Securities Report] Tokyo Okurasho Insatsukyoku, 1961, 1971, 1977, 1991.
28. Chugai Pharmaceutical Co., Chugai Seiyaku 75-nen no Ayumi [A 75-year History of Chugai Pharmaceutical]. Tokyo: Chugai Pharmaceutical Co., 2000.
29. Chugai Pharmaceutical Co., 'History'. http://www.chugai-pharm.co.jp/profile/about/history.html (accessed 4 May 2008).
30. Coleman, Samuel., Japanese Science: From the Inside. London: Routledge, 1999.
31. Coley, Wiliam Bradley., The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas: With a Report of Ten Original Cases. Philadelphia: Lea Brothers & Co., 1893.
32. Collins, Steven, and Hikoji Wakoh., 'Universities and Technology Transfer in Japan: Recent Reforms in Historical Perspective'. The Journal of Technology Transfer 25 (June 2000): 213-222.
33. Collins, Steven W., The Race to Commercialize Biotechnology: Molecules, Markets, and the State in the United States and Japan. London: RoutledgeCurzon, 2004.
34. Daiichi Pharmaceutical Co., Daiichi Seiyaku 70-nen no Ayumi [Daiichi Pharmaceutical, a 70-year History]. Tokyo: Daiichi Pharmaceutical Co., 1986.
35. Daiichi Pharmaceutical Co., Daiichi Seiyaku 80-nenshi [Daiichi Pharmaceutical, an 80-year History]. Tokyo: Daiichi Pharmaceutical Co., 1996.
36. Daiichi Pharmaceutical Co., Daiichi Seiyaku 90-nenshi [Daiichi Pharmaceutical, a 90-year History]. Tokyo: Daiichi Pharmaceuticals Co., 2007.
37. Daiichi Pharmaceutical Co., Yuka Shoken Hokokusho. Tokyo: Okurasho Insatsukyoku, 1986, 1991, 1996.
38. Daiichi Sankyo, Co., Annual Report 2009. Tokyo: Daiichi Sankyo Co., 2009.
39. Daiichi Sankyo, Co., Yuka Shoken Hokokusho. Tokyo: Okurasho Insatsukyoku, 2006.
40. Dainippon Pharmaceutical Co., Dainippon Seiyaku 100-nenshi [A One Hundred Year History of Dainihon Pharmaceutical]. Tokyo: Dainihon Pharmaceutical Co., 1993.
41. Dainippon Sumitomo Pharma Co., 'Kaisha Enkaku [Company History]'. http://www.ds- pharma.co.jp/profile/history.html (accessed 28 July 2008).
42. Dainippon Sumitomo Pharma Co., Yuka Shoken Hokokusho. Tokyo: Okurasho Insatsukyoku, 2006.
43. Danzon, Patricia, and Mark Pauly., 'Health Insurance and the Growth in Pharmaceutical Expenditures'. The Journal ofLaw and Economics 45, no. s2 (2002): 587-613.
44. Datamonitor., 'Chugai Pharmaceutical Co. Ltd'. Company Profile. London: Datamonitor, 2007.
45. Datamonitor., 'Global-Antibacterial Drugs'. Industry Profile. London: Datamonitor, 2002.
46. Datamonitor., 'Global-Cancer Drugs'. Industry Profile. London: Datamonitor, 2002.
47. Datamonitor., 'Global Pharmaceuticals'. Industry Profile. London: Datamonitor, 2005.
48. Datamonitor., 'Japan-Antibacterial Drugs'. Industry Profile. London: Datamonitor, 2002.
49. Datamonitor., 'Japan-Cancer Drugs'. Industry Profile, London: Datamonitor, 2002.
50. Datamonitor., 'Japan-Pharmaceuticals'. Industry Profile. London: Datamonitor, 2002.
51. Datamonitor., 'New Cars in the United States'. Industry Profile. London: Datamonitor, 2009.
52. Datamonitor., 'Pharmaceuticals in the United States'. Industry Profile. London: Datamonitor, 2009.
53. Datamonitor., 'Taiho Pharmaceuticals Co., Ltd'. Company Profile. London: Datamonitor, 2007.
54. Datamonitor., 'Takeda Pharmaceutical Company Limited'. Company Profile. London: Datamonitor, 2007.
55. Datamonitor., 'United Kingdom-Antibacterial Drugs'. Industry Profile. London: Datamonitor, 2002.
56. Datamonitor., 'United Kingdom-Cancer Drugs'. Industry Profile London: Datamonitor, 2002.
57. Datamonitor., 'United States-Antibacterial Drugs'. Industry Profile London: Datamonitor, 2002.
58. Datamonitor., 'United States-Cancer Drugs'. Industry Profile London: Datamonitor, 2002.
59. Datamonitor., 'Yakult Honsha Co., Ltd'. Company Profile. London: Datamonitor, 2007.
60. Dees, Bowen C., 'Japanese Science and Technology before 1945'. In The Allied Occupation and Japan 's Economic Miracle: Building the Foundations of Japanese Science and Technology, 1945-52, 1-11. Richmond: Japan Library, 1997.
61. Development Bank of Japan., 'Iyakuhin Gyökai no Genjö to Jenerikku Iyakuhin Shijö [The Current Status of the Pharmaceutical Industry and the Generics Market]'. Kongetsu no Topikkusu [Topic of the Month] report no. 145-2 (24 March 2010).
62. Dibner, M.D., 'Biotechnology in Pharmaceuticals: The Japanese Challenge'. Science 229, no. 4719 (1985): 1230-1235.
63. Drews, Jürgen., 'Drug Discovery: A Historical Perspective'. Science 287 (March 2000): 1960-1964.
64. Dunn, Christopher., Scrip's 1994 Review of Cancer Chemotherapy. Richmond: PJB Publications, 1994.
65. Eisai, Co., Annual Report 2009. Tokyo: Eisai, Co., 2009.
66. Elmsey, John., 'Flourine Helps the Medicine Go Down'. Independent, 18 March 1991.
67. Elwy, Todd S, Michael D. Fetters, Daniel W. Gorenflo and Tsukasa Tsuda., 'Cancer Disclosures in Japan: Historical Comparisons, Current Practices'. Social Science & Medicine 46 (September 1998): 1151-1163.
68. Endö, Hisao, Matsurö Oka, Masaki Ozawa, Yoshiaki Kamoya and Nobuo Tanaka., 'Iryöyö Iyakuhin Shijö ni Okeru Kyösö Keitai [Forms of Competition in the Ethical Pharmaceutical Market]'. In Iyakuhin Sangyö Soshikiron [On the Organisation of the Pharmaceutical Industry], edited by Tsurihiko Nanbu, 49-74. Tokyo: University of Tokyo Press, 2002.
69. Ennis, Thomas W., 'Dr. Kanematsu Sugiura, 89, Dies; A Pioneer in Cancer Chemotherapy; Research Dates to 1912'. The New York Times, 23 October 1979.
70. European Federation of Pharmaceutical Industries and Associations (EFPIA)., The Pharmaceutical Industry in Figures. Brussels: EFPIA, 1997, 2005.
71. Federal Trade Commission., United States. Economic Report on Antibiotics Manufacture. Washington: Government Printing Office, 1958.
72. Federation of Japan Pharmaceutical Wholesalers Association., 'Nihon Iyakuhin Oroshigyö Rengökai Kaiin Köseiinsu/Honshasu Suii [Changes in the Number of Member Firms/ Headquarters of the Federation of Japan Pharmaceutical Wholesalers Association]'. Federation of Japan Pharmaceutical Wholesalers Association. http://www.jpwa.or.jp/ jpwa/index.html (accessed 4 May 2007).
73. Feldman, Eric A., 'HIV and Blood in Japan, Transforming Private Conflict into Public Scandal'. In Blood Feuds: Aids, Blood and the Politics of Medical Disaster, 59-94. Oxford: Oxford University Press, 1999.
74. Feldman, Eric A., 'Medical Ethics the Japanese Way'. The Hastings Center Report 15, no. 5 (1985): 21-24.
75. Fleming, Alexander., 'On the Antibacterial Action of Cultures of a Penicillium, with Special Reference to Their Use in the Isolation of H. Influenzae'. British Journal ofExperimental Pathology 10 (June 1929): 226-236.
76. Foster, Jackson W., 'Three Days' Symposium on Penicillin Production, Held at Welfare Ministry, Tokyo, Japan, November 13-15, 1946'. Journal of Antibiotics 1 (March 1947): 1-8.
77. Frantz, Simon., 'The Trouble with Making Combination Drugs'. Nature Reviews Drug Discovery 5 (November 2006): 881-882.
78. Fuji Keizai., Iryoyo Iyakuhin Detabukku [Prescription Medicine Databook]. Tokyo: Fuji Keizai, 2005.
79. Fuji Keizai., 'Jenerikku Iyakuhin Kokunai Shijo no Shuyo 24 Yakko Ryoiki o Chosa [Investigating 24 Therapeutic Sectors in the Domestic Generic Medicines Market]'. https://www.fuji- keizai.co.jp/market/08096.html (accessed 7 May 2010).
80. Fujii, S., K. Ikenaka, M. Fukushima and T. Shirasaka., 'Effect of Uracil and its Derivatives on Antitumor Activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil'. Gann 69 (1978): 763-772.
81. Fujiki, Hideo, and Mitsuhiro Kida, eds., Yakuhin Kogai to Saiban: Saridomaido Jiken no Kiroku kara [Drug Accidents and Trials: From the Records of the Thalidomide Disaster]. Tokyo: University of Tokyo Press, 1974.
82. Fujisawa Pharmaceutical Co., Fujisawa Yakuhin 80-nenshi [Fujisawa Pharmaceutical, an 80-year History]. Osaka: Fujisawa Pharmaceutical Co., 1976.
83. Fujisawa Pharmaceutical Co., Fujisawa Yakuhin 100-nenshi [Fujisawa Pharmaceutical, a 100-year History]. Osaka: Fujisawa Pharmaceutical Co., 1995.
84. Fujisawa Pharmaceutical Co., YukaShokenHokokusho [Annual Securities Report]. Tokyo: Okurasho Insatsukyoku, 1960-1965, 1972, 1976, 1977.
85. Fukai, Saburo, ed., Konnichi no Shinyaku: Kindai Iyakuhin no Hensen [New Drugs Today: Changes in Modern Pharmaceutials]. Tokyo: Yakuji Jihosha, 1995.
86. Fukuhara, Hiroyuki., 'Iyakuhin no Sekai Hatsu Joshi kara Kakkokuni okeru Joshi made no Kikan [Time Differences between Initial Global Launches and Domestic Launches of Drugs across Different Countries]'. Research Paper Series, Office of Pharmaceutical Industry Research, Japan Pharmaceutical Manufacturers Association 31 (May 2006) .
87. Fukushima, Masanori., 'Clinical Trials in Japan'. Nature Medicine 1 (1995): 12-13.
88. Fukushima, Masanori., 'Sengo no Iyakuhin Ryutsushi: Doran ni Yoru Kakkyo to Ranbai Mondai no Hassei [The History of Distribution in the Pharmaceutical Industry: The Korean War Boom and Emerging Problems with Dumping]'. Iyaku Janaru 11 (June 1972): 40-54.
89. Fukushima, Masanori., 'Sengo no Iyakuhin Ryutsushi: Iyakuhin Kogyo no Kiki to Dakai e no Mosaku [The History of Distribution in the Pharmaceutical Industry: Seeking Solutions to the Challenges of the Pharmaceutical Industry]'. Iyaku Janaru 11 (September 1972): 44-53.
90. Fukushima, Masanori., 'Sengo no Iyakuhin Ryutsushi: Kajo Seisan ni Taisuru Shijo no Kakudai to Tosei no Hosaku [The History of Distribution in the Pharmaceutical Industry: Strategies for Controlling a Market Expanding with Overproduction]'. Iyaku Janaru 11 (July 1972): 58-70.
91. Fukushima, Masanori., 'The Overdose of Drugs in Japan'. Nature 342, no. 21 (December 1989): 850-851.
92. Galambos, Louis, and Jane Eliot Sewell., Networks of Innovation: Vaccine Development at Merck, Sharp & Dohme, and Mulford, 1895-1995. Cambridge: Cambridge University Press, 1996.
93. Gankanja Dantai Shien Kiko [Cancer Patients Support Organization]., 'Shui [Statement]'. Gankanja Dantai Shien Kiko http://www.canps.net/ (accessed 10 August 2007).
94. General Headquarters., Supreme Commander for the Allied Powers, Public Health and Welfare Section, J.M. Bransky Narcotic Investigator, Memorandum for Record, 'Conference Relative to Raising Standards of Pharmaceutical Education', 11 June 1946. Declassified EO 12065 Section 3-402/NNDG no. 775024 (NDL).
95. General Headquarters., B.N. Riordan Chief, Supply Division, Memorandum for Record, 'Meeting of Pharmaceutical Education Council', 19 July 1946, 17 January, 14 March 1947, 12 January, 6 July 1951. Declassified EO 12065 Section 3-402/NNDG no. 775024 (NDL).
96. General Headquarters., Charles Band Chief, Supply Division. Public Health and Welfare Section, Memorandum for Record, 'Reorganization of the Pharmaceutical and Supply Bureau: Ministry of Welfare', 26 March, 29 March, 1 October 1949. Declassified EO 12065 Section 3-402/NNDG no. 775024 (NDL).
97. General Headquarters., Mission and Accomplishments of the Occupation in the Public Health and Welfare Fields. Tokyo: Supreme Commander for the Allied Powers.
98. General Headquarters., Public Health and Welfare in Japan. Annual Summary: 1950. Tokyo: General Headquarters, Supreme Commander for the Allied Powers, Public Health and Welfare Section, 1950.
99. General Headquarters., Public Health and Welfare in Japan. Final Summary: 1951-1952. Tokyo: General Headquarters, Supreme Commander for the Allied Powers, Public Health and Welfare Section, 1952.
100. German Cancer Research Center., 'History'. German Cancer Research Center. http://www. dkfz.de/en/dkfz/geschichte.html (accessed 1 December 2007).
101. Gerschenkron, Alexander., Economic Backwardness in Historical Perspective: A Book of Essays. Cambridge, MA: Harvard University Press, 1962.
102. Gershell, Leland J. and Joshua H. Atkins., 'A Brief History of Novel Drug Discovery Technologies'. Nature Reviews Drug Discovery 2 (April 2003): 321-327.
103. Glaser, Martha., 'Market-share Battle Marks Cardiovasculars, Antiarthritics; 48th Annual Prescription Review'. Drug Topics 131 (March 1987): 43.
104. General Headquarters., 'Quinolones, Antidepressants Gained in 1988: PDS; Pharmaceutical Data Services'. Drug Topics 133 (April 1989): 73.
105. GlaxoSmithKline plc., Annual Report. London: GlaxoSmithKline plc., 2007.
106. Golec, Joseph, and John Vernon., 'Measuring US Pharmaceutical Industry R&D Spending'. Pharmacoeconomics 26, no. 12 (2008): 1005-1017.
107. Goodman, L.S., M.M. Wintrobe, W. Dameshek, M.J. Goodman, A. Gilman and M.T. McLennan., 'Nitrogen Mustard Therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, Lymphosarcoma, Leukemia, and Certain Allied and Miscellaneous Disorders'. Journal of the American Medical Association 105 (1946): 475-476.
108. Great Britain., Business Statistics Office. Industrial Research and Development Expenditure and Employment: 1975. London: HMSO, 1979.
109. Hara, Takuji., Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development. Cheltenham: Edward Elgar, 2003.
110. Hashimoto, Takehiko., 'The Hesitant Relationship Reconsidered: University-Industry Cooperation in Post-war Japan'. In Industrializing Knowledge: University-Industry Linkages in Japan and the United States, edited by Lewis M. Branscomb, Fumio Kodama and Richard L. Florida, 234-251. Cambridge, MA: MIT Press, 1999.
111. Hata, Toju, Fumikawa Koga, Yoshimoto Sano, Kokichi Kanamori, Akihiro Matsumae, Ryozo Sugawara, Tadashi Hoshi, Tatsuo Shima, Shinya Ito and Setsuo Tomizawa., 'Carzinophilin, New Tumor Inhibitory Substance Produced by Streptomyces'. Journal of Antibiotics 7 (August 1954): 107-112.
112. Hata, Toju, Yoshimoto Sano, Ryozo Sugawara, Akihiro Matsumae, Kokichi Kanamori, Tatsuo Shima and Tadashi Hoshi., 'Mitomycin, a New Antibiotic from Streptomyces I'. Journal of Antibiotics, Series A 9 (July 1956): 141-146.
113. Hawkins, Elma S., and Michael R. Reich., 'Japanese-originated Pharmaceutical Products in the United States from 1960 to 1989: An Assessment of Innovation'. Clinical Pharmacology and Therapeutics 51 (January 1992): 1-11.
114. Helfand, W. H., H.B. Woodruff, K.M.H. Coleman and D.L. Owen., 'Wartime Industrial Development of Penicillin in the United States'. In The History of Antibiotics: A Symposium, edited by John Parascandola, 31-55. Madison: American Institute of the History of Pharmacy, 1980.
115. Higgs, Gerry., 'Molecular Genetics: the Emperor's Clothes of Drug Discovery?' Drug Discovery Today 9 (September 2004): 727-729.
116. Hillaby, John., 'Cancer Increase is not Clear-cut; World Congress in London Attributes Some of it to Regular Check-ups'. The New York Times, 9 July 1958.
117. Hilts, Philip., The FDA, Business, and One Hundred Years ofRegulation. New York: Knopf, 2003.
118. Hirai, Keiji, Akira Ito, Yasuo Abe, Seigo Shizue, Tsutomu Irikura, Matsuhisa Inoue and Susumu Mitsuhashi., 'Comparative Activities of AM-715 and Pipemedic and Nalidixic Acids against Experimentally Induced Systemic and Urinary Tract Infections'. Antimicrobial Agents and Chemotherapy 19, no. 1 (1981): 188-189.
119. Hobby, Gladys L., and Milton Wainwright., Penicillin: Meeting the Challenge. New Haven: Yale University Press, 1985.
120. Holdridge, Geoffrey M., ed., JTEC/WTEC Annual Report and Program Summary, 1993/1994. Baltimore: Japan Technology Evaluation Center, 1994.
121. Hooper, David C. and Ethan Rubinstein., 'Introduction'. In Quinolone Antimicrobial Agents, viii-ix. Washington DC: American Society for Microbiology Press, 2003.
122. Howells, Jeremy, and Ian Neary., Intervention and Technological Innovation: Government and the Pharmaceutical Industry in the UK and Japan. Basingstoke: Macmillan, 1995.
123. Ichikawa, Tokuji., 'Bureomaishin no Shokai [An Introduction to Bleomycin]'. Gan no Rinsho 14, no. 4 (1968): 295-296.
124. Ikegami, Naoki, and John Creighton Campbell., 'Health Care Reform in Japan: The Virtues of Muddling Through'. Health Affairs 18 (May/June 1999): 56-75.
125. IMS Health., IMS Health Midas, December 2009.
126. Inagaki, Haruhiko., Hekiso: Kokusan Penisirin Kaihatsu no Hatafuri, Inagaki Gun'i Shosa to Ichikosei Gakuto Doin [Hekiso: Pioneering the Development of Penicillin in Japan, Lieutenant Medic Inagaki and the Mobilised Students of the Imperial University]. Tokyo: Nikkei Jigyo Shuppan Senta, 2005.
127. Inagaki, Katsuhiko., Interview by Kihachiro Shimizu. 'Nihon ni Okeru Penishirin Kaihatsu no Keii [The Development of Penicillin in Japan]'. Today's Therapy 19, no. 2 (1995): 26-34.
128. Inagaki, Katsuhiko., Interview by Nihon Penishirin Kyokai. 'Penisirin no Nihon Inyu [The Transfer of Penicillin into Japan]'. In Nihon Penishirin Kyokai [Japan Penicillin Association]. Penishirin noAyumi: 1946-1961 [The History of Penicillin: 1946-1961]. Tokyo: Nihon Penishirin Kyokai, 1961.
129. Inoue, Tadashi., 'Iryoyo Iyakuhin Shijo no Tokushusei to Ryutsu Kaikaku [Special Features ofthe Prescription Pharmaceutical Market and Distribution Reform]'. Waseda Shakaigaku Kenkyü 49 (October 1994): 55-65.
130. Institute of Microbial Chemistry., Institute of Microbial Chemistry: 1962-1977. Tokyo: Center for Academic Publications, 1977.
131. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)., http://www.ich.org (accessed 15 May 2007) .
132. Ishidate, M., K. Kobayashi, Y Sakurai, H. Sato and T. Yoshida., 'Experimental Studies on Chemotherapy of Malignant Growth Employing Yoshida Sarcoma Animals (II). The Effect of N-oxide derivatives of Nitrogen Mustard'. Proceedings of the Japan Academy 27 (1951): 493-498.
133. Ishii, Shinichi., 'Kigyo no Gaiburenkei ni taisuru Ninshiki to Gaiburenkei no Jisshi: Sangakurenkei to Iyakuhin Kigyo o Chushin to Shita Hikakubunseki [The Perception and Reality of External Collaborations: A Comparative Analysis of University-Industry Collaborations in the Pharmaceutical Industry]'. Keiei Kenkyü 53, no. 3 (2002): 205217.
134. Ito, Akira, Keiji Hirai, Matsuhisa Inoue, Hiroshi Koga, Seigo Suzue, Tsutomu Irikura and Susumu Mitsuhashi., 'In Vitro Antibacterial Activity of AM-715, a New Nalidixic Acid Analog'. Antimicrobial Agents and Chemotherapy 17, no. 2 (1980): 103-108.
135. Ito, M., 'Nichi-bei-o ni Okeru Kokinyaku no Rinshohyokaho [A Clinical Evaluation of Antibacterial Agents in the United States, Europe and Japan]'. Saishin Igaku 44, no. 12 (1989): 2453-2498.
136. Japan, House of Councillors., Health and Welfare Committee, Official Report of Debates. 93rd Diet, 9th Session, 25 November 1980.
137. Japan, House of Councillors., Health and Welfare Committee Official Report of Debates., 95th Diet, 3rd Session, 27 October 1981.
138. Japan, House of Councillors., Official Report of Debates. 126th Diet, 7th Session, 20 April 1993.
139. Japan, House of Councillors., Health and Welfare Committee Official Report of Debates. 126th Diet, 11th Session, 30 June 1993.
140. Japan, House of Representatives., Health and Welfare Committee. Official Report of Debates. 94th Diet, 20th Session, 30 July 1981.
141. Japan, House of Representatives. Health and Welfare Committee, Official Report of Debates. 104th Diet, 4th Session, 6 March 1986.
142. Japan, House of Representatives., Health and Welfare Committee Official Report of Debates. 126th Diet, 6th Session, 2 April 1993.
143. Japan Antibiotics Research Association., 'Honkai no Gaiyo [About Us]'. Japan Antibiotics Research Association. http://www.antibiotics.or.jp/jara/news/jara.htm (accessed 28 April 2008) .
144. Japan Bioindustry Association., Baiobencha Tokei Hokokusho 2005 [Statistical Report on Bioindustries]. Tokyo: Japan Bioindustry Association, 2006.
145. Japan Business History Association., Banyü Seiyaku 85-nenshi [Banyu Pharmaceutical, an 85-year History]. Tokyo: Banyu Pharmaceutical Co., 2002.
146. Japan Cancer Association., 'Gangakkai no Rekishi [The History of the Japan Cancer Association]'. Japan Cancer Association. http://www.jca.gr.jp/b01.html (accessed 1 December 2007).
147. Japanese Board of Cancer Therapy., 'Ninteii Seido Kisoku [Certified Oncologist Regulations]'. Japanese Board of Cancer Therapy. http://www.jbct.jp/sys_regulation01. html (accessed 30 November 2007).
148. Japanese Society of Medical Oncology., 'Nihon Rinshö Shuyö Gakkai Gan Yakubutsu Ryöhö Senmon'i Ninteisha [JSMO Medical Oncology Certificate List]'. http://jsmo. umin.jp/senmoni/lists.html (accessed 9 April 2010).
149. Japan External Trade Organisation., The Survey on Access to Japan: Pharmaceuticals. Tokyo: Japan External Trade Organisation, 1998.
150. Japan Fair Trade Commission., Shuyö Sangyö ni Okeru Ruiseki Seisan Shüchüdo [Concentration Ratio of Main Industries]. Tokyo: Japan Fair Trade Commission, 1975-1994. http://www.jftc.go.jp/katudo/ruiseki/ruisekidate.html (accessed 1 June 2008).
151. Japan Pharmaceutical Association., Iyakuhin Bungyö Shinchoku Jökyö [Progress on the Separation on the Prescribing and Dispensing of Medicines]. Japan Pharmaceutical Association. http://www.nichiyaku.or.jp/contents/bungyo/default.html (accessed 20 April 2008).
152. Japan Pharmaceutical Manufacturers Association., Japan, House of Representatives., JPMA Databook. Tokyo: JPMA, 2007, 2009.
153. Japan Pharmaceutical Manufacturers Association., Seiyakukyö 20-nen no Ayumi [A 20-year History of the Japan Pharmaceutical Manufacturers Association]. Tokyo: Japan Pharmaceutical Manufacturers Association, 1988.
154. Jihö., Iryö Iyakuhin Gyökai no Ippan Chishiki [General Information on the Health Care and Pharmaceutical Industries]. Tokyo: Jihö, 2005.
155. Jihö., YakujiHandobukku [Pharmaceutical Affairs Handbook]. Tokyo: Jihö, 2000-2009.
156. Johnson, Chalmers A., MITI and the Japanese Miracle: The Growth of Industrial Policy, 1925-1975. Stanford, CA: Stanford University Press, 1982.
157. Kataoka, Ichirö, Mitsuaki Shimaguchi and Mimura Yumiko, eds., Iyakuhin Ryütsüron [Studies on Distrubution in the Pharmaceutical Industry]. Tokyo: University of Tokyo Press, 2003.
158. Katö, Benzaburö., 'Innen no Döri ni Rikkyaku Shita Jigyö Keiei [Business Management Based on the Philosophy of Fate]'. In Gendai Toppu Keiei no Jigyö Tetsugaku [Business Philosophies among Today's Leading Managers], edited by Nihon Jitsugyö Shuppansha. Tokyo: Nihon Jitsugyö Shuppansha, 1969.
159. Kazis, Dimitris., Post-war Industrial Policy and the Electronics Industry in Japan. Athens: Centre of Planning and Economic Research, 1988.
160. Keizai Shunjusha, ed., Meiji Hyakunen Kigyö no Rekishi [Company Histories 100 Years after Meiji]. Tokyo: Keizai Shunjusha, 1968.
161. Kida, Mitsushiro., Thalidomide Embryopathy in Japan. Tokyo: Kodansha, 1987.
162. Kiese, Manfred., 'Chemotherapie mit Antibakteriellen Stoffen aus Niederen Pilzen und Bakterien'. Journal ofMolecularMedicine 22 (1943): 505-511.
163. Kleinfeld, N.R., 'Intense Battle for Antibiotics'. The New York Times, 13 June 1983.
164. Kneller, Robert., 'Autarkic Drug Discovery in Japanese Pharmaceutical Companies: Insights into National Differences in Industrial Innovation'. Research Policy 32 (2003): 1805-1827.
165. Kneller, Robert., 'The Beginning of University Entrepreneurship in Japan: TLOs and Bioventures Lead the Way'. Journal of Technology Transfer 32 (2007): 435-456.
166. Kneller, Robert., 'University-Industry Collaboration in Biomedical Research in Japan and the United States: Implications for Biomedical Industries'. In Industrializing Knowledge: University-Industry Linkages in Japan and the United States, edited by Lewis M. Branscomb, Fumio Kodama and Richard L. Florida, 410-438. Cambridge, MA: MIT Press, 1999.
167. Koga, Shösuke., 'Yakujihösei no Hensen [Changes to the Pharmaceutical Affairs Act]'. Gekkan Yakuji 21 (November 1979): 31-40.
168. Koinuma, Nobuo., 'Gan Iryo no Keizaiteki Hyoka [Economic Evalutaion of Cancer Treatments]'. Koshu Eisei 71, no. 2 (February 2007): 108-112.
169. Koseisho 50-nenshi Henshu Iinkai [Editorial Committee for the 50-year History of the Ministry of Health and Welfare]. 'Jiyuka to Kokusaika no Shinten [Progress in Capital Liberalisation and Internationalisation]'. In Koseisho 50-nenshi [A 50-year History of the Ministry of Health and Welfare], 1624-1626. Tokyo: Kosei Mondai Kenkyukai, 1988.
170. Koyama, Yasuo, Akio Kurosasa, Atsushi Tsuchiya and Kinsuke Takakuta., 'A New Antibiotic "Colistin" Produced by Spore-forming Soil Bacteria'. The Journal of Antibiotics 3, no. 7 (1950): 457-459.
171. Kreuger, Anne., 'The Political Economy of the Rent-seeking Society'. American Economic Review 64 (June 1974): 291-303.
172. Kumazawa, Joichi, and Morimasa Yagisawa., 'The History of Antibiotics: The Japanese Story'. Journal of Infection and Chemotherapy 8, no. 2 (2002): 125-133.
173. Kureha Chemical Industry Co., Kureha Kagaku 50-nenshi [A 50-year History of Kureha Chemical Industry]. Tokyo: Kureha Chemical Industry Co., 1995.
174. Kureha Chemical Industry Co., YukaShokenHokokusho [Annual Securities Report]. Tokyo: Okurasho Insatsukyoku, 1976.
175. Kushida, Kenji., 'Japanese Entrepreneurship: Changing Incentives in the Context of Developing a New Economic Model'. Stanford Journal of East Asian Affairs 1 (Spring 2001): 86-95.
176. Kyorin Pharmaceutical Co., Yuka Shoken Hokokusho [Annual Securities Report]. Tokyo: Okurasho Insatsukyoku, 1995.
177. Kyowa Hakko Co., Bara wa Bara: Kyowa Hakko 35-nenshi [A Rose is a Rose: A 35-year History of Kyowa Hakko]. Tokyo: Kyowa Hakko Co., 1984.
178. Kyowa Hakko Co., BaraYuka Shoken Hokokusho [Annual Securities Report]. Tokyo: Okurasho Insatsukyoku, 1965, 1966.
179. Landau, Ralph, Basil Achilladelis, and Alexander Scriabine, eds., Pharmaceutical Innovation: Revolutionizing Human Health. Philadelphia: Chemical Heritage Press, 1999.
180. Laubach, Gerald D., 'Federal Regulation and Pharmaceutical Innovation'. Proceedings of the Academy of Political Science 33, no. 4 (1980): 60-80.
181. Laurence, William L., 'Science in Review: Reports of Progress in Fight on Cancer Hold Out Hope of Cutting Death Toll'. The New York Times, 13 July 1958.
182. Liebenau, Jonathan., 'The British Success with Penicillin'. Social Studies of Science 17, no. 1 (1987): 69-86.
183. Liebenau, Jonathan., 'Industrial R&D in Pharmaceutical Firms in the Early Twentieth Century'. Business History 26, no. 3 (November 1984): 329-346.
184. Lieberman Marvin B. and David B. Montgomery., 'First-mover Advantages'. Strategic Management Journal 9, no. 1 (1988): 41-58.
185. Lieberman Marvin B. and David B. Montgomery., 'First-mover (Dis)advantages: Retrospective and Resource-based View'. Strategic Management Journal 19, no. 12 (1998): 1111-1125.
186. Life Insurance Association of Japan., Seimeihoken Jigyo Gaikyo [Summary of Life Insurance Business]. Tokyo: Life Insurance Association of Japan, 1957-2008.
187. Lipartito, Kenneth., 'Culture and the Practice of Business History'. Business and Economic History 24, no. 2 (1995): 1-42.
188. Lohr, Steve., 'Merck's Big Venture in Japan'. New York Times, 13 October 1983.
189. Longe, Jacqueline L. and Deirdre S. Blanchfield, eds., The Gale Encyclopedia of Medicine. 2nd ed. Farmington Hills, MI: Gale Group, 2001.
190. Low, Morris, Shigeru Nakayama and Hitoshi Yoshioka, eds., Science, Technology and Society in Contemporary Japan. Cambridge: Cambridge University Press, 1999.
191. Lynn, Matthew., The Billion-dollar Battle: Merck v Glaxo. London: Mandarin, 1992.
192. Lynskey, Michael., 'The Commercialisation of Biotechnology in Japan: Bioventures as a Mechanism of Knowledge Transfer from Universities'. International Journal of Biotechnology 6 (2004): 155-185.
193. Macfarlane, Gwyn., Alexander Fleming: The Man and the Myth. Oxford: Oxford University Press, 1984.
194. Maddison, Angus, and Organisation for Economic Co-operation and Development Centre. The World Economy. Vol. 2. Paris: Organisation for Economic Co-operation and Development, 2006.
195. Maeda, K., and H. Umezawa., 'The Crystal Structure of Kanamycin'. Tetrahedron Letters 15 (1968): 1875-1879.
196. Management and Coordination Agency., Statistics Bureau and Statistics Centre. Kagaku Gijutsu KenkyU Chosa Hokoku [Report on the Survey of Research and Development]. Tokyo: Management and Coordination Agency, 1985-2000.
197. Marsh, Peter., 'Pharmaceuticals 6; Optimistic But Still Some Way to Go'. Financial Times, 1 October 1987.
198. Martin, Peter., 'Weak Link in the Chain: Distribution Difficulties Have Meant that Japan's Successes in the West's Car and Consumer Electronics Markets Have Not Been Equalled in Other Industries'. Financial Times, 6 March 1997.
199. Mason, Mark., American Multinationals in Japan: The Political Economy of Japanese Capital Controls. Cambridge, MA: Harvard University Press, 1992.
200. Matsumoto, Tadamasa., 'Wagasha ni Okeru Koganzai no Kaihatsu'. Kagaku to Kogyo (April 1976): 105-107.
201. Matsumura, Katsuhiro., 'Seiyaku Kigy o no Keiei Kiban Ky oka Katei, Showa 25-nen Zenhan kara 30-nen Goro made [Pharmaceutical Firms Strengthen the Foundations of Business, from the Early 1950s to around 1955]'. Iyaku Janaru 12 (May 1973): 46-52.
202. Matsumura, Katsuhiro., 'Seiyaku Kigyo no Saihen Seibi to Gorika Katei, Showa 20-nen kara 25-nen zenhan made [The Reorganisation and Rationalisation of the Pharmaceutical Industry, from 1945 to early 1950]'. Iyaku Janaru 12 (March 1973): 42-48.
203. Matsuo, Katsuichi., 'Korisuchin oyobi Korisuchin Metan Suruhonsan Natoriumu no Kaihatsu [The Development of Colistin and Colistin Methanesulfonate]'. In Sangyo Gijutsu no Rekishi no Shutaisei-Taikeika o Okonaukoto ni yoru Inobeshon Soshutsu no Kankyo Seibi ni Kansuru Chosa Kenkyu Hokokusho [Investigation and Research Report on the Compilation and Organisation on the History of Industrial Technology to Develop an Environment More Suitable for Innovation], edited by Japan Machinery Federation, 74-80, 242-275. Tokyo: Japan Machinery Federation, 2006.
204. Matsuyama, Kotone, Tetsuji Sadaike and Masanori Fukushima., 'The Present Approval State of Anti-tumour Drugs in Japan'. Rinsho Hyoka [Clinical Evaluation] 31 (2004): 579-586.
205. Maurer, P. Reed., 'Positive News on "Dramatic" Wholesaler Restructuring in Japan Overlooked'. PharmaMarketletter, 20 November 2003.
206. Maurer, P. Reed., 'Why Japanese Pharmaceutical Wholesalers Merge'. Pharma Marketletter, 4 June 1999.
207. Meiji Seika Kaisha, Ltd., Meiji Seika no Ayumi: Kaukide Tsukutte 60-nen [A History of Meiji Seika: Selling What We Want to Buy for 60 Years]. Tokyo: Meiji Seika Kaisha, Ltd, 1977.
208. Meiji Seika Kaisha, Ltd., Meiji Seika no Ayumi: Sogyo kara 70-nen [A History of Meiji Seika: 70 Years since Establishment]. Tokyo: Meiji Seika Kaisha, Ltd, 1987.
209. Meiji Seika Kaisha, Ltd., Meiji Seika no Ayumi: Sogyo kara 80-nen [The History of Meiji Seika: 80 Years from Establishment]. Tokyo: Meiji Seika Kaisha, Ltd, 1997.
210. Meiji Seika Kaisha, Ltd., YukaShokenHokokusho [Annual Securities Report]. Tokyo: Okurasho Insatsukyoku, 1960.
211. Merck & Co., 2005Annual Report. Whitehouse Station: Merck & Co., 2006.
212. Merck KGaA., '2006 Online Report: Commercial Unit Oncology'. Merck KGaA. http:// www.merck.de/servlet/PB/menu/1647870/index.html (accessed 6 December 2007).
213. Methe, David T. and Joan D. Pinner-Hahn., 'Globalization of Pharmaceutical Research and Development in Japanese Companies: Organizational Learning and the Parent-Subsidiary Relationship'. In Japanese Multinationals Abroad: Individual and Organizational Learning, by Schon Beechler and Allan Bird, 191-210. New York: Oxford University Press, 1999.
214. Michaels, Adrian., 'Warner Bows to Pfizer Demand for Merger Talks'. Financial Times, 14 January 2000.
215. Ministry of Economy Trade and Industry., Boeki Doko Detabesu [Database on Trends in Trade], http://www.meti.go.jp/policy/trade_policy/trade_db/index.html (accessed 20 November 2010).
216. Ministry of Education., Kyoiku Shihyo no Kokusai Hikaku [International Comparison of Education Benchmarks]. Tokyo: Office of the Prime Minister, 1985-2005.
217. Ministry of Education., Culture, Sports, Science and Technology. 'Incorporation of National Universities'. In FY2003 White Paper on Education, Culture, Sports, Science and Technology. Tokyo: Ministry of Education, Culture, Sports, Science and Technology, 2004.
218. Ministry of Health and Welfare., 'Application of Standards for the Implementation of Clinical Trials on Pharmaceutical Products'. Notification no. 445 of Pharmaceuticals and Cosmetics Division/Notification no. 68 of the Safety Division, Pharmaceutical Affairs Bureau, 29 May 1997.
219. Ministry of Health and Welfare., 'Densenbyo oyobi Shokuchudoku no Kanjasu to Shiboshasu [Patients and Deaths of Infectious Diseases and Food Poisoning] (1876-1999)'. Statistics Bureau, Ministry of International Affairs and Communications. http://www.stat.go.jp/data/chouki/24.htm (accessed 20 March 2007).
220. Ministry of Health and Welfare., 'Iyakuhin [Pharmaceuticals]'. In Isei Hyakunenshi [A 100-year History of Administration in Medicine], 447-451. Tokyo: Gyosei, 1976.
221. Ministry of Health and Welfare., 'Iyakuhin no Kenkyu Kaihatsu no Shien: Gutaiteki na Shiensaku [Supporting R&D in Pharmaceuticals: Specific Support Policies]', in Kosei Hakusho (1988), http:// wwwhakusyo.mhlw.go.jp/wpdocs/hpaz198701/b0053.html (accessed 15 November 2010).
222. Ministry of Health and Welfare., Iyakuhin Sangyo Jittai Chosa Hokoku [Report on the Status of the Pharmaceutical Industry]. Tokyo: Ministry of Health and Welfare, 1988-2000.
223. Ministry of Health and Welfare., JinkoDotaiShakaiKeizaimen Chosa [Social and Economic Study of Vital Statistics]. Tokyo: Ministry of Health and Welfare, 1994.
224. Ministry of Health and Welfare., Kanja Chosa [Patient Survey]. Tokyo: Ministry of Health and Welfare, 1953-1985.
225. Ministry of Health and Welfare., Kosei Hakusho [White Paper on Health and Welfare]. Tokyo: 1957-2000. Hakusho nado Detabesu Shisutemu [Full-text System for White Papers, etc.] http://wwwhakusyo. mhlw.go.jp/wp/index.htm (accessed 8 November 2010).
226. Ministry of Health and Welfare., 'Pharmaceutical Business Facilities (C.Y. 1944-1996, F.Y. 1997-2004)'. http://www. stat.go.jp/data/chouki/24.htm (accessed 27 July 2008).
227. Ministry of Health and Welfare., Saikin no Yakumu Gyosei [Recent Trends in Pharmaceutical Administration]. Tokyo: Yaukumu Kohosha, 1968-1998.
228. Ministry of Health and Welfare., 'Standards for the Implementation of Clinical Trials on Pharmaceutical Products'. MHW Ordinance no. 28, 27 March 1997.
229. Ministry of Health and Welfare., Yakkyokuho, Dairokuji Kaisei [Japanese Pharmacopoeia, 6th revision]. Tokyo: Ministry of Health and Welfare, 1951.
230. Ministry of Health and Welfare., Yakuji Kogyo Seisan Dotai Chosa Tokei [Annual Survey on Production in the Pharmaceutical Industry]. Tokyo: Yakugyo Keizai Kenkyujo, 1953-1967.
231. Ministry of Health and Welfare., Yakuji Kogyo Seisan Dotai Chosa Tokei [Annual Survey on Production in the Pharmaceutical Industry]. Tokyo: Yakugyo Keizai Kenkyujo, 1968-2000.
232. Ministry of Health and Welfare., Yakumu Koho [Bulletin of Pharmaceutical and Supply Bureau]. Tokyo: Yakumu Kohosha, 1949-2000.
233. Ministry of Health, Labour and Welfare., 'Deaths by Leading Cause of Death, Population and Households'. http://www.stat.go.jp/english/data/chouki/02.htm (accessed 1 December 2007).
234. Ministry of Health, Labour and Welfare., yakuhin Sangyo Bijon [Vision Statement for the Pharmaceutical Industry]. Tokyo: Ministry of Health, Labour and Welfare, 2002.
235. Ministry of Health, Labour and Welfare., Iyakuhin Sangyo Jittai Chosa Hokoku [Report on the Status of the Pharmaceutical Industry]. Tokyo: Ministry of Health, Labour and Welfare, 2001-2006.
236. Ministry of Health, Labour and Welfare., 'Kako 5-nenkan ni Gakkai/Kanjadantai kara no Soki Shonin no Yobo ga Ari, katsu Heisei 17-nen 3-gatsu Izen ni Obei 4-kakoku de Shonin Sareta Mishoninyaku [Drugs Requested by Academic/Patient Organiations for Accelerated Approval Within the Past 5 Years, that were Approved in the 4 American and European Countries Prior to, During or Before March 2005]'. http://www.mhlw.go.jp/shingi/2005/03/s0331-13.html (accessed 1 December 2007).
237. Ministry of Health, Labour and Welfare., KoseiRodoHakusho [White Paper on Health, Labour and Welfare]. Tokyo: Okurasho Insatsukyoku, 2001-2007. http://www.mhlw.go.jp/wp/hakusyo/index.html (accessed 8 November 2010).
238. Ministry of Health, Labour and Welfare., Shin Iyakuhin Sangyo Bijon [New Vision Statement on the Pharmaceutical Industry]. Tokyo: Ministry of Health and Welfare, 2007.
239. Ministry of Health, Labour and Welfare., Yakuji Kogyo Seisan Dotai Chosa Tokei [Annual Survey on Production in the Pharmaceutical Industry]. Tokyo: Jiho, 2001-2006.
240. Ministry of Health, Labour and Welfare., Yakumu Koho [Bulletin of Pharmaceutical and Supply Bureau]. Tokyo: Yakumu Kohosha, 2001-2006.
241. Ministry of Internal Affairs and Communications., Statistics Bureau. Kagaku Gijutsu Kenkyu Chosa Hokoku [Report on the Survey of Research and Development]. Tokyo: Ministry of Internal Affairs and Communications, 2001-2006.
242. Ministry of Internal Affairs and Communications., 'Nenrei Kakusai Danjobetsu Jinko [Population by Single Years of Age and Sex] (1884-2000)'. http://www.stat.go.jp/data/chouki/02.htm (accessed 20 March 2007).
243. Ministry of International Trade and Industry., Tsusho Hakusho [White Paper on Trade]. Tokyo: Okurasho Insatsukyoku, 1958-1973.
244. Ministry of International Trade and Industry., TsushoHakusho [White Paper on Trade]. Tokyo: Gyosei, 1974-2000.
245. Mitsibishi Bank, Ltd., 'Nihon Shijo ni Churyoku suru Iyakuhin Gaishi [Foreign Pharmaceutical Firms Eye the Japanese Market'. Mitsubishi Bank Research Report 369 (January 1986): 22-32.
246. Mitsubishi Pharma Corp,. Yuka Shoken Hokokusho. Tokyo: Okurasho Insatsukyoku, 2006.
247. Miyamoto, Mamoru., 'Kongo Shinsatsu ni Tsuite [On Mixed Billing]'. Kansai Daigaku Keizai-kei 226 (September 2006): 77-85.
248. Miyasaka, Tadashi, and Seigo Sawada., 'Anticancer Agent Irinotecan'. Gendai Kagaku [Current Chemistry] 343 (October 1999): 58-66.
249. Miyata, Shinpei,. 'Yoshida Tomizo: Shinjidai o Hiraita Yoshida Nikushu [Tomizo Yoshida: Yoshida Carcinoma and the Beginning of a New Era]'. Gekkan Gan 33 (September 2002): 42-45.
250. Mizuho Corporate Bank, Ltd., 'Obei Seiyaku Kigyo no Saihen Doko to Wagakuni Seiyakugyokai e no Inpurikeshon'. Mizuho Sangyo Chosa 17 (March 2005): 1-42.
251. Motohashi, Kazuyuki., 'Japan's Patent System and Business Innovation: Reassessing Propatent Policies'. RIETI Discussion Paper Series 03-E-020, http://www.rieti.go.jp/en/ publications/act_dp2003.html (accessed 15 May 2008).
252. Motohashi, Kazuyuki., 'Baiobencha no Katsudo ni Kansuru Nichibei Hikakubunseki [A Comparison of Bioventures in Japan and the United States]'. Iryo to Shakai 17, no. 1 (2008): 55-70.
253. Nakagawa, Takeshi., Interview by Shozo Tsunabuchi in 'Meiji Seika: Ishokudogen Baio o Mezasu [Meiji Seika Aims to Develop Biotechnology Businesss]'. Will (December 1982): 48-51.
254. Nakajima, Mitsuyoshi., 'Chiken no Shitsuteki Reberuappu no tame no Teian: Kontorora no Tachiba kara [Suggestions to Improve the Quality of Clinical Trials: From a Controller's Standpoint]'. Yakuri to Chiryo 23, no. 4 (1995): 777-783.
255. Nakamoto, Michiyo., 'Global Reach through Tie-ups: Japan'. Financial Times, 30 April 2002.
256. Nakamoto, Michiyo, and David Pilling., 'Drugs Market Set for Change: Japan's Pharma Industry is Slowly Opening Up'. Financial Times, 3 April 2002.
257. Nakamura, Yoshiaki, and Hiroyuki Odagiri., 'Nihon no Biobencha Kigyo: So no Igi to Jittai [Japanese Bioventures: Meaning and Current Status]'. REITIDiscussion Paper Series 22 (June 2002): 1-52.
258. Nakane, Chie., Japanese Society. Tokyo: Charles E. Tuttle, 1984.
259. Nakano, Shigeyuki., 'Chiken ni Sanka Suru Hikensha no Meritto [Patient Benefits to Participating in Clinical Trials]'. Yakuri to Chiryo 23, no. 5 (1995): 1085-1093.
260. Nakao, Isao, Tadashi Yokoyama, Ichiro Urushizaki, Akira Wakui, Hisashi Furue, Yoshiyuki Koyama, Kiyoji Kimura, Nobuya Ogawa and Tatsuo Saito., 'Shinko Igan ni Taisuru PSK no Rinsho Koka [Clinical Effects of PSK in Advanced Gastric Cancer]'. Oncologia 14 (1985): 163-170.
261. Nakayama, Shigeru, and Morris Low., 'The Research Function of Universities in Japan'. Higher Education 34 (1997): 245-258.
262. Nanbu, Tsuruhiko., 'Iyakuhin no Sangyo Soshiki: Yakka Kisei no Keizaiteki Koka [Industrial Organisation in Pharmaceuticals: The Consequences of Price Regulation in Japan]'. Iryo to Shakai 7 (January 1997): 1-15.
263. Nanbu, Tsuruhiko., ed. Iyakuhin Sangyo Soshikiron [Studies on the Organization of the Pharmaceutical Industry]. Tokyo: University of Tokyo Press, 2002.
264. National Cancer Center., 'Cancer Statistics in Japan, 2007'. National Cancer Center. http:// ganjoho.ncc.go.jp/public/statistics/backnumber/2007_en.html (accessed 1 December 2007).
265. National Cancer Institute., 'Biological Therapies for Cancer: Questions and Answers'. National Cancer Institute. http://www.cancer.gov/cancertopics/factsheet/Therapy/ biological#q3 (accessed 26 May 2008).
266. National Cancer Institute., 'Developmental Therapeutics Program, FDA Approved Drugs'. National Cancer Institute. http://dtp.nci.nih.gov/timeline/flash/FDA.htm (accessed 10 November 2007).
267. National Cancer Institute., 'Dictionary of Cancer Terms'. National Cancer Institute. http://www.cancer.gov/dictionary/ (accessed 20 March 2007).
268. National Cancer Institute., 'Dictionary of Cancer Terms: Antitumor Antibiotic'. http://www.cancer.gov/templates/db_alpha.aspx?CdrID=44488 (accessed 26 May 2008).
269. National Cancer Institute., 'The National Cancer Institute Act, 1937-2007: Celebrating 70 Years of Excellence in Cancer Research'. National Cancer Institute. http://www.cancer.gov/aboutnci/ncia (accessed 1 December 2007).
270. National Cancer Institute., 'What Is Cancer?' http://www.cancer.gov/cancertopics/what-is-cancer (accessed 10 July 2008).
271. National Health Service., 'Medical and Dental Staff 2008 Detailed Results'. http://www. ic.nhs.uk/statistics-and-data-collections/workforce/nhs-staff-numbers/nhs-staff-1998- 2008-medical-and-dental (accessed 10 April 2010).
272. National Science Foundation (United States)., Survey of Industrial Research and Development Historical Database 1953-1998. http://www.nsf.gov/statistics/iris (accessed 13 November 2009).
273. Neimeth, Robert., 'Japan's Pharmaceutical Industry Postwar Evolution'. In The Changing Economics of Medical Technology, edited by Annetine Gelijns and Ethan Halm, Committee on Technological Innovation in Medicine, Institute of Medicine, 155-168. Washington DC, National Academies Press, 1991.
274. Neu, Harold C., 'The Crisis in Antibiotic Resistance'. Science 257, no. 5073 (1992): 1064-1073.
275. Nihon Kogakukai [Japan Federation of Engineering Societies]., MeijiKogyoshi [History of Industry in the Meiji Period]. Tokyo: Nihon Kogakukai, 1925.
276. Nihon Penishirin Kyokai [Japan Penicillin Association]., Penishirin no Ayumi: 1946-1961 [The History of Penicillin: 1946-1961]. Tokyo: Nihon Penishirin Kyokai, 1961.
277. Nihon Yakushi Gakkai [The Japanese Society for the History of Pharmacy]., Nihon Iyakuhin Sangyoshi [The History of the Japanese Pharmaceutical Industry]. Tokyo: Yakuji Nipposha, 1995.
278. Niimoto, Minoru, Takao Hattori, Ryuichiro Tanida, Koyoshi Inokuchi and Nobuya Ogawa., 'Igan Chiyu Setsujo Shorei ni Taisuru Maitomaishin C, Futorafuru, Kuresuchin o Mochiita Jutsugo Men'eki Kagaku Ryoho [Postoperative Immunotherapy for Curatively Resected Gastric Cancer Patients Using Mitomycin C, Ftorafur and Krestin]'. Oncologia 14 (1985): 171-180.
279. Nippon Kayaku Co., Nippon Kayaku no Ayumi: Kono 10-nen o Chushin ni Shite [The History of Nippon Kayaku: With Special Attention to the Past 10 Years]. Tokyo: Nippon Kayaku Co., 1976.
280. Nippon Kayaku Co., YukaShokenHokokusho [Annual Securities Report]. Tokyo: Okurasho Insatsukyoku, 1950, 1951, 1974, 1979.
281. Nippon Medical School, Research Institute of Vaccine Therapy for Tumors and Infectious Diseases., 'Maruyama Vaccine'. Nippon Medical School. http://vaccine.nms.ac.jp/ (accessed 1 December 2007).
282. Nishida, Minoru, Tadao Matsubara, Takeo Murakawa, Yasuhiro Mine, Yoshiko Yokota, Sachiko Goto and Shogo Kuwahara., 'Cefazolin, a New Semisynthetic Cephalopsorin Antibiotic II. In Vitro and In Vivo Antimicrobial Activity'. The Journal of Antibiotics 23, no. 3 (1970): 137-148.
283. Nishikawa, Takashi., Kusuri Kara Mita Nihon; Showa 20-nendai no Genfukei to Konnichi [Looking at Japan from 'Medicine': Scenes from the 1940s to the Present]. Tokyo: Yakuji Nipposha, 2004.
284. Nishimura, Sey., 'Censorship of Medical Journals in Occupied Japan'. Journal of the American Medical Association 274, no. 6 (August 1995): 454-456.
285. Nishimura, Shuzo., 'Iryo Sangyo [The Healthcare Industry]'. In Sengo Nihon Sangyoshi [A History of Japanese Industries in the Post-war Period], edited by Sangyo Gakkai [The Society for Industrial Studies], 769-786. Tokyo: Toyo Keizai Shinposha, 1995.
286. Nitta, Kazuo, Kuniichiro Yano, Fumio Miyamoto, Yoshiharu Hasegawa, Toshihisa Sato, Noriko Kamoto and Shintaro Matsumoto., 'A New Antibiotic, Josamycin. II: Biological Studies'. The Journal of Antibiotics Series A 20, no. 3 (1967): 181-187.
287. Nitta, Shinji., 'Iyakuhin no Shinsa Gyosei [Administering the Examination of Pharmaceuticals]'. Gekkan Yakuji21 (November 1979): 53-65.
288. Oberlaender, Christian., 'The Rise of Western "Scientific Medicine" in Japan: Bacteriology and Beriberi'. In Building a Modern Japan: Science, Technology and Medicine in the Meiji Era and Beyond, edited by Morris Low, 11-36. New York: Palgrave Macmillan, 2005.
289. Odagiri, Hiroyuki., 'Iyakuhin Sangyo ni okeru Araiansu [Alliances in the Pharmaceutical Industry]'. Iryo to Shakai 17, no. 1 (2008): 3-18.
290. Odagiri, Hiroyuki., 'Nihon no Biobencha Kigyo: Sono Igi to Jittai [Japanese Bioventures: Meaning and Current Status]'. REITI Discussion Paper Series 02-J-007 (June 2002).
291. Office of Pharmaceutical Industry Research., 'Seiyaku Sangyo no Shoraizo [The Future Image of the Pharmaceutical Industry]'. Office of Pharmaceutical Industry Research, Japan Pharmaceutical Manufacturers Association (May 2007).
292. Office of Pharmaceutical Industry Research., 'Soyaku no Ba to shite no Kyosoryoku Kyoka ni Mukete [Creating a Stronger, More Competitive Environment for Drug Discovery]'. Office of Pharmaceutical Industry Research, Japan Pharmaceutical Manufacturers Association (November 2005).
293. Office of the Prime Minister, Bureau of Statistics., Kagaku Gijutsu Kenkyu Chosa Hokoku [Report on the Survey of Research and Development]. Tokyo: Office of the Prime Minister, 1961-1984.
294. Ohnuki-Tierney, Emiko., Illness and Culture in Contemporary Japan. Cambridge: Cambridge University Press, 1984.
295. Okamoto, H., M. Minami, S. Shoin, S. Koshimura and R. Shimizu., 'ExperimentalAnticancer Studies Part XXXI. On the Streptococcal Preparation Having Potent Anticancer Activity'. Japanese Journal of Experimental Medicine 36 (1966): 175-186.
296. Okamoto, H., S. Shoin, M. Minami, S. Koshimura and R. Shimizu., 'Experimental Anticancer Studies Part XXX. Factors Influencing the Streptolysin S-forming Ability of Streptococci Having Anticancer Activity'. Japanese Journal of Experimental Medicine 36 (1966): 161-174.
297. Okamoto, Hajime, Susumu Shoin, Saburo Koshimura and Ryusaku Shimizu., 'Studies on the Anticancer and Streptolysin S-forming Abilities of Hemolytic Streptococci'. Japanese Journal of Microbiology 11, no. 4 (1967): 323-326.
298. Okimoto, Daniel I., Between MITI and the Market: Japanese Industrial Policy for High Technology. Stanford, CA: Stanford University Press, 1989.
299. Ono, Shunsuke., 'The Performance of the Japanese New Drug Review System: From the Reviewer's Perspective'. RinshoHyoka [Clinical Evaluation] 31 (2004): 557-566.
300. Organisation for Economic Co-operation and Development., Health at a Glance 2009: OECD Indicators. Paris: Organisation for Economic Co-operation and Development, 2009.
301. Organisation for Economic Co-operation and Development., International Trade by Commodities Statistics Database, http://www.sourceoecd.org (accessed 20 May 2010).
302. Organisation for Economic Co-operation and Development., Pharmaceuticals: Gaps in Technology. Paris: Organisation for Economic Cooperation and Development, 1969.
303. Osono, Takashi, Yoshihiko Oka, Shunichi Watanabe, Yozo Numazaki, Kiruko Moriyama, Hitoshi Ishida, Kiyoshi Suzaki, Yoshiro Okami and Hamao Umezawa., 'A New Antibiotic Josamycin I: Isolation and Physicochemical Characteristics'. The Journal of Antibiotics Series A 20, no. 3 (1967): 174-180.
304. Otsuka Pharmaceutical Co., Kessan Joho [Financial Information]. http://www.otsuka.co.jp/ company/profile/finance/ (accessed 10 May 2009).
305. Otsuka Pharmaceutical Co., 'The Extent and History of Foreign Direct Investment in Japan'. Foreign Direct Investment in Japan. Cambridge: Cambridge University Press, 2008.
306. Parascandola, John, ed., History of Antibiotics: A Symposium. Madison: American Institute of the History of Pharmacy, 1980.
307. Pharmaceutical Research and Manufacturers of America., Pharmaceutical Industry Profile 2008. Washington DC: Pharmaceutical Research and Manufacturers of America, March 2008.
308. Pfizer., Inc. Annual Review. New York: Pfizer, Inc., 2006.
309. PJB Publications., Scrip's Antibacterial Report. London: PJB Publications, 1990.
310. PJB Publications., Scrip: Pharmaceutical Company League Tables. Richmond: PJB Publications, 1991.
311. PJB Publications., Scrip: Yearbook. Richmond: PJB Publications, 1988, 1991.
312. Podolsky, M. Lawrence, and Daniel E. Koshland., 'The Oxford Incidents'. In Cures out of Chaos: How Unexpected Discoveries Led to Breakthroughs in Medicine and Health, 177-224. Amsterdam: Harwood, 1997.
313. Rapoport, Carla., 'Chugai-a Portfolio of Pills'. Financial Times, 22 September 1983.
314. Reich, Michael., 'Why the Japanese Don't Export More Pharmaceuticals: Health Policy as Industrial Policy'. California Management Review 32, no. 2 (1990): 124-150.
315. Rhoads, C.P., 'Nitrogen Mustards in the Treatment ofNeoplastic Disease: Official Statement'. Journal of the American Medical Association 131 (1946): 656-658.
316. Sams, Crawford F., Interview by Darryl Podoll, 3 May 1979. Interview OH037, transcript, Washington University School ofMedicine Oral History Project, Bernard Becker Medical Library, St Louis, Missouri, http://beckerexhibits.wustl.edu/oral/interviews/sams.html (accessed 8 November 2010).
317. Sams, Crawford F. and Zabelle Zakarian., 'Medic': The Mission of an American Military Dofctor in Occupied Japan and Wartorn Korea. London: M.E. Sharpe, 1998.
318. Sankyo Co., Sankyo 80-nenshi [Sankyo, an 80-year History]. Tokyo, Sankyo Co., 1979.
319. Sankyo Co., Sankyo 100-nenshi [Sankyo, a 100-year History]. Tokyo: Sankyo Co., 1999.
320. Sankyo Co., YukaShokenHokokusho [Annual Securities Report]. Tokyo: Okurasho Insatsukyoku, 1960, 1991.
321. Saruta, Takao., 'Chiken no Shitsuteki Reberuappu no tame no Teian: Tantoi no Tachiba kara [Suggestions to Improve the Quality of Clinical Trials: From a Physician's Standpoint]'. Yakuri to Chiryo 23, no. 3 (1995): 561-564
322. Sasaki, Satoshi, Toshihiro Imaeda, Yoji Hayase, Yoshiaki Shimizu, Shizuo Kasai, Nobuo Cho, Masataka Harada, Nobuhiro Suzuki, Shuichi Furuya and Masahiko Fujino., 'A New Class of Potent Nonpeptide Luteinizing Hormone-releasing Hormone (LHRH) Antagonists: Design and Synthesis of 2-phenylimidazo[1, 2-a]pyrimidin-5-ones'. Bioorganic & Medicinal Chemistry Letters 12 (August 2002): 2073-2077.
323. Sato, K., Y. Matsuura, M. Inoue, T. Une, Y. Osada, H. Ogawa and S. Mitsuhashi., 'In Vitro and In Vivo Activity of DL-8280, a New Oxazine Derivative'. Antimicrobial Agents and Chemotherapy 22, no. 4 (1982): 548-553.
324. Schatz, Albert, Elizabeth Bugie and Selman Waksman., 'Streptomycin, a Substance Exhibiting Antibiotic Activity against Gram-positive and Gram-negative Bacteria'. Proceedings of the Society for Experimental Biology and Medicine 55 (1944): 66-69.
325. Schmitt, Eric., 'What's Hot in Imported Products; Antibiotics Made Jointly'. The New York Times, 30 November 1986.
326. Seimei Hoken Bunka Senta., Seimei Hoken ni Kansuru Zenkoku Jittai Chosa [National Survey on Life Insurance]. Tokyo: Seimei Hoken Bunka Senta, 1965-2009.
327. Seiyaku Kigyo Kondankai [Council of Pharmaceutical Firms]., Seiyaku Kigyo no Genjo to Kosatsu [An Evaluation of the Current Status of Pharmaceutical Firms]. Tokyo: Seiyaku Kigyo Kondankai, 1965.
328. Shimizu, Kihachiro., 'Nihon ni Okeru Penishirin Kaihatsu no Keii [The Development of Penicillin in Japan]'. Today's Therapy 19, no. 2 (1995): 26-34.
329. Shionogi & Co., Yuka Shoken Hokokusho [Annual Securities Report]. Tokyo: Okurasho Insatsukyoku, 1960.
330. Shinnippon Hoki Publishing Co., YakkaKijun [Official Drug List]. Tokyo: Shinnippon Hoki Publishing Co., 1977-1990.
331. Shirasaka, Tetsuhiko., S1 Tanjo [Creating S-1]. Tokyo: Evidensu, 2006.
332. Sigurdson, Jon., Future Advantage Japan?: Technology Strategies for Pharmaceutical and Chemical Corporations. London: Cartermill, 1996.
333. Sneader, Walter., Drug Discovery: A History. Chichester: John Wiley & Sons, 2005.
334. Soda, Hajime., 'Ishinki no Seiyaku [Manufacturing Pharmacy during the Times of the Meiji Restoration]'. Iyaku Janaru 11 (August 1972): 38-42.
335. Soda, Hajime., 'Ishinki no Seiyaku [Manufacturing Pharmacy during the Times of the Meiji Restoration]'. Iyaku Janaru 11 (September 1972): 57-60.
336. Soda, Hajime., 'Ishinki no Seiyaku [Manufacturing Pharmacy during the Times of the Meiji Restoration]'. Iyaku Janaru 11 (November 1972): 58-63.
337. Sugimura, Takashi., 'Gankenkyu ni Kansuru Shomondai to Shohansei [Comments on Cancer Research in Japan]'. Tanpakushitsu Kakusan Koso 23, no. 6 (1978), 685-691.
338. Sugimura, T., 'Pioneers of Cancer Research in Japan'. Japanese Journal of Cancer Research 82 (December 1991): 1448-1449.
339. Steslicke, William E., 'Doctors, Patients, and Government in Modern Japan'. Asian Survey 12, no. 11 (1972): 913-931.
340. Sugawara, Ryozo, and Toju Hata., 'Mitomycin C, a New Antibiotic from Streptomyces II'. Journal of Antibiotics, Series A 9 (July 1956): 147.
341. Suguro, Toshihiko., 'Kureha Kagaku Kogyo: Daikokubashira "Kuresuchin" Gekigen no Kiki [Kureha Chemical Industry: Sales of Core Product "Krestin" May Plummet]'. Shukan Toyo Keizai, 12 May 1990, 139-141.
342. Sumitomo Trust & Banking Co., 'Kakudai suru Jenerikku Iyakuhin Gyokai no Yukue [The Future of the Expending Generics Market]'. Chosa Geppo (January 2006).
343. Sunday Times Insight Team., Suffer the Children: The Story of Thalidomide. London: Andre Deutsch, 1979.
344. Swinbanks, David., 'Japanese Doctors Keep Quiet'. Nature 339 (June 1989): 409.
345. Swinbanks, David., 'Restrictions Recommended'. Nature 342 (December 1989): 843.
346. Swinbanks, David., 'Japan's Foundations Still Building'. Nature 361 (February 1993): 761-764.
347. Tabuchi, Kaoru., 'GMP no Ayumi to sono Tenbo [History and Prospects of GMP]'. Gekkan Yakuji 21 (November 1979): 243-247.
348. Taiho Pharmaceutical Co., 'Taiho Yakuhin no Ayumi [A History of Taiho Pharmaceutical]'. Taiho Pharmaceutical Co. http://www.taiho.co.jp/corporation/history/index.html (accessed 2 December 2007).
349. Takahashi, Hidenao., 'Iyakuhin no Juyo no Kakaku Danryokusei no Suikei [The Price Elasticity of Demand in Pharmaceuticals: An Examination of the Biennial Price Reductions]'. Hitotsubashi University COE Working Paper 12 (August 2005).
350. Takahashi, Hisashi, Isao Hayakawa and Takeshi Akimoto., 'The History of the Development and Changes of Quinolone Antibacterial Agents'. Yakushigaku Zasshi 38, no. 2 (2003): 161-179.
351. Takahashi, Takao., 'Medical Business Ethics: The HIV-tainted Blood Affair in Japan'. In Taking Life and Death Seriously: Bioethics from Japan, edited by Takao Takahashi, 253-273. Amsterdam: Elsevier, 2005.
352. Takeda, Chobei., 'Wagakuni no Iyakuhin Kogyo to Boeki [Pharamceutical Industry and Trade in Our Country]'. Kankeiren 16 (January 1949): 19-21.
353. Takeda Pharmaceutical Co., Annual Report 2006.Tokyo: Takeda Pharmaceutical Co. 2006.
354. Takeda Pharmaceutical Co., Annual Report 2009. Osaka: Takeda Pharmaceutical Co., 2009.
355. Takeda Pharmaceutical Co., 'Beikoku Jigyo Saihen ni Tsuite [On the Reorganisation of US Operations]'. 2 July 2008. Press release. http://www.takeda.co.jp/press/article_28213.html (accessed 30 July 2008).
356. Takeda Pharmaceutical Co., Takeda 180-nenshi [A 180-year History of Takeda]. Osaka: Takeda Pharmaceutical Co., 1962.
357. Takeda Pharmaceutical Co., Takeda 200-nen [200 Years of Takeda]. Osaka: Takeda Pharmaceutical Co., 1984.
358. Takeda Pharmaceutical Co., 'Takeda Establishes New Global Pharmaceutical R&D Center in US'. 25 December 2003. Press release. http://www.takeda.com/press/article_801.html (accessed 16 July 2008).
359. Takeda Pharmaceutical Co., 'Takeda no Rekishi [A History of Takeda]'. Takeda Pharmaceutical Co. http://www. takeda.co.jp/about-takeda/history/article_79.html (accessed 30 November 2007).
360. Takeda Pharmaceutical Co., 'Takeda Submits a New Drug Application for a Fixed-dose Combination Tablet of Actos with Sulfonylurea in Japan'. 27 July 2009. Press release.
361. Takeda Pharmaceutical Co., YukaShokenHokokusho [Annual Securities Report]. Tokyo: Okurasho Insatsukyoku, 1960.
362. Takemae, Eiji., Inside GHQ: The Allied Occupation of Japan and its Legacy. London: Continuum, 2002.
363. Takeuchi, Yutaka, Yoshiaki Takebayashi, Makoto Sunagawa, Yutaka Isobe, Yukari Hamazume, Akura Uemura and Tetsuo Noguchi., 'The Stability of a Novel Carbapenem Antibiotic, Meropenem (SM-7338), in a Solid State Formulation for Injection'. Chemical & Pharmaceutical Bulletin 41, no. 11 (1993): 1998-2002.
364. Tanaka, Shumei., 'Iyakuhin no Ryutsu o Meguru Mondaiten [Problems in Pharmaceutical Distribution]'. In Shakai Yakugaku Nyumon, 156-168. Tokyo: Nankodo, 1987.
365. Tatsuta, Kuniaki, and Morimasa Yagisawa., Koseibusshitsu: Seisan no Kagaku [Antibiotics: The Science of Production]. Tokyo: Nihon Kagakukai [The Chemical Society of Japan], 1994.
366. Teff, H., and C.R. Munro., Thalidomide: The Legal Aftermath. Farnborough: Saxon House, 1976.
367. Terada, Kiyoshi., 'Ensan Irinotekan [Irinotecan Hydrochloride]'. Fine Chemical 29 (September 2000): 31-41.
368. Thomas, III, Lacy Glenn., 'Implicit Industrial Policy: The Triumph of Britain and the Failure of France in Global Pharmaceuticals'. Industrial and Corporate Change 3, no. 2 (1994): 451-489.
369. Thomas, III, Lacy Glenn., 'Spare the Rod and Spoil the Industry: Vigorous Competition and Vigorous Regulation Promote Global Competitive Advantage'. First Boston Working Paper Series 90-03, 1990.
370. Thomas, III, Lacy Glenn., The Japanese Pharmaceutical Industry: The New Drug Lag and the Failure of Industrial Policy. Northampton: Edward Elgar, 2001.
371. Thomson Reuters., The Japanese Generic Drug Market: Opportunities and Strategies for Success. London: Thomson Reuters, 2009.
372. Thompson, Nigel., International Price Comparison: Japan. Tokyo: Japan Pharmaceutical Manufacturers Association Long Term Vision Research Council, 1999.
373. Timmermans, Stefan, and Valerie Leiter., 'The Redemption of Thalidomide: Standardizing the Risk of Birth Defects'. Social Studies of Science 30, no. 1 (February 2000): 41-71.
374. Todaka, Koji., '"GRP" Nihon ni okeru Yakuzai Kaihatsu no Infura to shite no Ishi no Yakuwari ["GRP" The Role of Physicians in Helping to Develop Drugs in Japan]'. Rinsho Hyoka 31, no. 3 (2004): 567-571.
375. Tokai Bank, Ltd., 'Hanbai-mo no Kyoka o Isogu Iyakuhinkai [The Pharmaceutical Industry Rushes to Strengthen its Distribution Network]'. Tokai Ginko Chosa Geppo 222 (January 1966): 17-26.
376. Travis, John., 'Reviving the Antibiotic Miracle?' Science 264, no. 5157 (1994): 360-362.
377. Tsunematsu, Kinoichi., 'Saihen Katei no Iyakuhin Sangyo [The Pharmaceutical Industry under Reorganisation]'. Iyaku Janaru 9 (September 1970): 20-23.
378. Tsunematsu, Kinoichi., 'Senryoka ni Okeru Yakuji Eisei Taisaku [Public Health and Welfare Policy under the Occupation]'. Iyaku Janaru 9 (July 1970): 56-58.
379. Tsunoda, Fusako., Hekiso: Nihon PenishirinMonogatari [Hekiso: The Story of Penicillin in Japan]. Tokyo: Shinchosha, 1978.
380. Ueda, Eiji. 'Wagakuni no Chiken no Genjo to Mondaiten [The Current Environment and Issues around Clinical Trials in Japan]'.ModanMedia 50, no. 2 (2004): 10-13.
381. Umezawa, Hamao., 'Kanamycin', in Saikin no Shinyaku [New Drugs in Japan], edited by Yakuji Nipposha (Tokyo: Yakuji Nipposha, 1959), 13-17.
382. Umezawa, Hamao., 'Kanamycin: Its Discovery'. Annals of the New York Academy of Sciences 76, no. 2 (1958): 20-26.
383. Umezawa, Hamao., 'Kosei Busshitsu no Kenkyushi (1) [A History of Research in Antibiotics (1)]'. Shizen 17, no.2 (1962): 83-89.
384. Umezawa, Hamao., 'Kosei Busshitsu no Kenkyushi (2) [A History of Research in Antibiotics (2)]'. Shizen 17, no. 3 (1962): 78-89.
385. Umezawa, Hamao., 'Kosei Busshitsu o Motomete (1): [Searching for Antibiotics (1)]'. Shokun 1, no. 1 (1980): 282-299.
386. Umezawa, Hamao., 'Kosei Busshitsu o Motomete (2): Kanamaishin no Hakken [Searching for Antibiotics (2): The Discovery of Kanamycin]'. Shokun 1, no. 2 (1980): 294-305.
387. Umezawa, Hamao., 'Koseibusshitsu o Motomete (3): Michi no Ryoiki Gan e no Chosen [Searching for Antibiotics (3): Challenging Cancer]'. Shokun 12, no. 3 (1980): 230-244.
388. Umezawa, Hamao., 'Seiganzai wa Dokomade Kitaka [The Status of Anticancer Drugs]'. Kagaku Asahi (September 1982): 50-54.
389. Umezawa, Hamao, Kenji Maeda, Tomio Takeuchi and Yoshiro Okami., 'New Antibiotics, Bleomycin A and B'. Journal of Antibiotics, Series A 19 (September, 1966): 200-209.
390. Umezawa, Hamao, Masahiro Ueda, Kenji Maeda, Koki Yagishita, Shinichi Kondo, Yoshiro Okami, Ryozo Itahara, Yasuke Osato, Kazuo Nitta and Tomio Takeuchi., 'Production and Isolation of a New Antibiotic, Kanamycin'. The Journal of Antibiotics Series A 10 (September 1957): 181-188.
391. US Congress, Office of Technology Assessment., Commercial Biotechnology: An International Assessment. Washington DC: US Government Printing Office, 1984.
392. US Department of Commerce., Pharmaceutical Price Controls in OECD Countries: Implications for US Consumers, Pricing, Research and Development, and Innovation. Washington DC: US Department of Commerce, 2004.
393. US Department of Commerce, Bureau of the Census., Statistical Abstract of the United States 1940. Washington DC: US Government Printing Office, 1941.
394. US Department of Commerce, Bureau of the Census., 'Concentration Ratios in Manufacturing'. US Census Bureau. http://www.census. gov/epcd/www/concentration.html (accessed 1 December 2007).
395. US Department of Commerce, Bureau of the Census., Scientific Research and Development Services, 2002, Washington, DC: US Census Bureau. http://www.census.gov/prod/ec02/ec0254i07.pdf (accessed 22 November 2009).
396. US Department of Commerce, International Trade Administration, Market Access and Compliance., 'MOSS Agreement on Medical Equipment and Pharmaceuticals'. United States Department of Commerce. http://www.mac.doc.gov/japan/source/menu/ medpharm/ta860109.html (accessed 15 May 2007).
397. US Department of Commerce, International Trade Administration, Office of Japan Market Access and Compliance., 'U.S.-Japan Structural Impediments Initiative (SII)'. United States Department of Commerce. http://www.mac.doc.gov/japan/market-opening/mar- ket-opening.htm (accessed 2 May 2008).
398. US Food and Drug Administration, Center for Drug Evaluation and Research., 'CDER Drug and Biological Approval Reports'. http://www.fda.gov/cder/rdmt/default.htm (accessed 4 May 2008).
399. US Food and Drug Administration, Center for Drug Evaluation and Research., 'Colorectal Cancer Endpoints Workshop Summary, 12 November 2003'. US Food and Drug Administration. http://www.fda.gov/cder/drug/cancer_endpoints/colonEnd- pointsSummary.htm (accessed 16 May 2006).
400. US Food and Drug Administration, Center for Drug Evaluation and Research., 'FDA Oncology Tools Approval Summary for Bleomycin'. US Food and Drug Administration. http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID= 208 nnk (accessed 10 November 2007).
401. US Food and Drug Administration, Center for Drug Evaluation and Research., 'FDA Oncology Tools Approval Summary for Mitomycin C'. US Food and Drug Administration. http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID= 273 (accessed 10 November 2007).
402. US Food and Drug Administration, Center for Drug Evaluation and Research., 'Label and Approval History'. US Food and Drug Administration. http://www. accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ ApprovalHistory#apphist (accessed 8 May 2008).
403. Vogel, Steven Kent., Japan Remodeled: How Government and Industry are Reforming Japanese Capitalism. Ithaca, NY: Cornell University Press, 2006.
404. Wakaki, Shigetoshi., 'Tosha ni Okeru Seiganzai no Kenkyu to Kaihatsu no Genjo [The Status ofAnticancer Drug R&D at Our Company]'. Kagaku Kogyo (April 1976): 96-98.
405. Wakaki, S., H. Marumo and K. Tomioka., 'Isolation of New Fractions of Antitumour Mitomycins' Antibiotics and Chemotherapy 8, no. 8 (1958): 228-240.
406. Wakasugi, Ryuhei and Harue Wakasugi., 'Iyakuhin no Kenkyu Kaihatsu to Hoseido [Pharmaceutical R&D and the Legal System]'. Mitagakkai Zasshi 99, no. 1 (April 2006): 57-74.
407. Wall, Monroe E. and M.C. Wani., 'Camptothecin: Discovery to Clinic'. Annals of the New York Academy of Sciences 803 (13 December 1996): 1-12.
408. Wall, Monroe E., M.C. Wani, C. E. Cook, Keith H. Palmer, A.T. McPhail and G.A. Sim., 'Plant Antitumour Agents 1: The Isolation and Structure of Campothecin, a Novel Alkaloidal Leukemia and Tumour Inhibitor from Camptotheca Acuminata'. Journal of American Chemical Society 88 (20 August 1966): 3888-3890.
409. Westney, Eleanor., 'Country Patterns in R&D Organization: The United States and Japan'. In Country Competitiveness: Technology and the Organizing of Work, edited by Bruce Kogut, 36-53. Oxford: Oxford University Press, 1993.
410. White, G. Philip., Antibiotics: Market Review and Development Trends. London: FT Healthcare, 1999.
411. Wilson, Jenny., Antibacterial Products and Markets, Scrip Reports. Richmond: PJB Publications, 1997.
412. Woodruff, Barry., 'A Soil Microbiologist's Odyssey'. Annual Review of Microbiology 35 (1981): 1-28.
413. World Health Organization., Global TB Database. http://www.who.int/tb/country/global_ tb_database/en/index.html (accessed 1 November 2007).
414. Yagisawa, Morimasa., 'Antibiotics, Chemotherapeutics and Other Microbial Products Originated from Japan'. Unpublished document.
415. Yagisawa, Morimasa., 'Biseibutsu Taisha Sanbutsu Tansaku Kenkyu no Doko [Trends in Exploratory Research of Microbial Metabolite Part 2; 20 Years after Antibiotics]'. Baiosaiensu to Indasutori 58, no. 2 (2000): 89-94.
416. Yagisawa, Yukimasa., 'Early History of Antibiotics in Japan'. In The History of Antibiotics: A Symposium, edited by John Parascandola, 69-90. Madison: American Institute of the History of Pharmacy, 1980.
417. Yagisawa, Yukimasa., 'Shinbunya o Kirihiraita Koseibusshitsu [A New Field Created by Antibiotics]'. Iyaku Janaru 9 (February 1970): 20-23.
418. Yakugai Konzetsu Foramu., Yakugai Eizu wa Naze Okitaka [Why the HIV Drug Tragedy Occurred]. Tokyo: Kirishobo, 1996.
419. Yakugyo Jihosha., Nihon no Iyakuhin Sangyo [The Japanese Pharmaceutical Industry]. Tokyo: Yakugyo Jihosha, 1973.
420. Yakugyo Jihosha., Yakuji Handobukku [Pharmaceutical Affairs Handbook]. Tokyo: Yakugyo Jihosha, 1968-1999.
421. Yakugyo Keizai Kenkyujo., Yakugyo Keizai Nenkan [Economics of the Pharmaceutical Industry Annual]. Tokyo: Yakuji Nipposha, 1967, 1971, 1979, 1984, 1987.
422. Yakugyo Keizai Kenkyujo., Yakuji Nenkan [Pharmaceutical Affairs Annual]. Tokyo: Nihon Yakugyo Shimbunsha, 1951, 1957, 1961, 1964.
423. Yakuji Kenkyukai., Saikin no Yakumu Gyosei [Recent Trends in Pharmaceutical Administration]. Tokyo: Yakumu Kohosha. 1999-2005.
424. Yakuji Nipposha., Saikin no Shinyaku [New Drugs in Japan]. Tokyo: Yakuji Nipposha, 1950-2006.
425. Yakuji Nipposha., The Japanese Pharmaceutical Industry in the New Millennium. Tokyo: Yakuji Nipposha, 2001.
426. Yakuji Nipposha., 'Enkaku [History]'. Yakult Honsha Co. http://www.yakult.co.jp/front/ company/profile/htm/index03.html (accessed 15 November 2007).
427. Yakuji Nipposha., Yakuji Nipposha., 'Yakult Honsha Iyakuhin Jigyo Setsumeikai Sanko Shiryo [Reference Materials for the Informational Meeting on the Pharmaceutical Business at Yakult Honsha]'. Tokyo: Yakult Honsha Co., 14 June 2006.
428. Yakuji Nipposha., YukaShokenHokokusho [Annual Securities Report]. Tokyo: Okurasho Insatsukyoku, 1990.
429. Yakuseki Nipposha., Yakugyo Nenkan [Pharmaceutical Industry Annual]. Tokyo: Yakuseki Nipposha, 1935, 1938.
430. Yamanouchi Pharmaceutical Co., Yamanouchi Seiyaku 50-nenshi [A 50-year History of Yamanouchi Pharmaceutical]. Tokyo: Yamanouchi Pharmaceutical Co., 1975.
431. Yamanouchi Pharmaceutical Co., Yuka Shoken Hokokusho [Annual Securities Report]. Tokyo: Okurasho Insatsukyoku, 1950, 1961, 1971, 1976, 1981.
432. Yamazaki, Toru., 'Sengo Yakugyoshi [A Postwar History of the Pharmaceutical Industry] (1)'. Yakkyoku 16, no. 8 (August 1965): 3-8.
433. Yamazaki, Toru., 'Sengo Yakugyoshi [A Postwar History ofthe Pharmaceutical Industry] (2)'. Yakkyoku 16, no. 9 (September 1965): 7-12.
434. Yamazaki, Toru., 'Sengo Yakugyoshi [A Postwar History ofthe Pharmaceutical Industry] (3)'. Yakkyoku 16, no. 10 (October 1965): 7-12.
435. Yamazaki, Toru., 'Sengo Yakugyoshi [A Postwar History ofthe Pharmaceutical Industry] (4)'. Yakkyoku 16, no. 11 (November 1965): 7-12.
436. Yano Keizai Kenkyujo., Iyaku Sangyo Nenkan [Pharmaceutical Industry Annual]. Tokyo: Yano Keizai Kenkyujo, 1975, 1980, 1985.
437. Yano Keizai Kenkyujo., Iyakuhinshijo Senryaku no tame no Maketingu Deta Nenpo [Marketing Data Annual for Strategizing in the Pharmaceutical Market]. Tokyo: Yano Keizai Kenkyujo, 1985.
438. Yano Keizai Kenkyujo., 'Koryoku ga Yowai kara Tsukawareru, Kuresuchin, Pishibaniru [Krestin and Picibanil Used because of Weak Effects]'. Iyaku Sangyo Nenkan (1985): 15-18.
439. Yasuda, Kuniaki., 'Nihon ni Okeru Shiniyakuhin no Shonin Shinsa Kikan [Approval Times for New Drugs in Japan]'. Research Paper Series, Office of Pharmaceutical Industry Research, Japan Pharmaceutical Manufacturers Association 35 (December 2006).
440. Yongue, Julia., 'Research Culture in the Pharmaceutical Industry'. Kenkyu Gijutsu, Keikaku 8, no. 3 (1993): 239-248.
441. Yongue, Julia., 'Origins of Innovation in the Japanese Pharmaceutical Industry: The Case of Yamanouchi Pharmaceutical Company (1923-1976)'. Japanese Research in Business History 22 (2005): 109-136.
442. Yongue, Julia., 'Shinyaku Kaihatsu o Meguru Kigyo to Gyosei: Chiken o Chushin ni [Firms and Government in Drug Development: An Examination of Clinical Trials]'. In Kigyo Bunseki to Gendai Shihon Shugi [Corporate Analysis and Contemporary Capitalism], edited by Akira Kudo and Motoi Ihara, 166-191. Kyoto: Minerva, 2008.
443. Yoshida, T., H. Sato and M. Ishidate., 'Yoshida Nikushu ni yoru Akusei Shuyo Kagakuryoho no Jikkenteki Kenkyu 1 [Experimental Studies on Chemotherapy of Malignant Growth Employing Yoshida Sarcoma 1'. Gann 41 (1950): 93-96.
444. Yoshida, Tomizo., 'Cancer Research in Japan'. Cancer Research 16, no. 11 (1956): 10071008.
445. Yoshitomi Pharmaceutical Industries, Ltd., Yoshitomi Seiyaku 50-nen no Ayumi [A 50-year History of Yoshitomi Pharmaceutical]. Tokyo: Yoshitomi Pharmaceutical Industries, Ltd, 1990.
446. Yoshitomi Pharmaceutical Industries, Ltd., YukaShokenHokokusho [Annual Securities Report]. Tokyo: Okurasho Insatsukyoku, 1949, 1960, 1961.
447. Zeria Pharmaceutical Co., 'Enkaku [Company History]'. Zeria Pharmaceutical Co. http:// www.zeria.co.jp/comp/co01.html (accessed 1 December 2007).
448. Zeria Pharmaceutical Co., Yuka Shoken Hokokusho [Annual Securities Report]. Tokyo: Okurasho Insatsukyoku, 1990.